Backgrounds/Aims: Since most transplantation studies for alcoholic liver disease (ALD) were performed on deceased donor liver transplantation, little was known following living donor liver transplantation (LDLT). Methods: The clinical outcome of 18 ALD patients who underwent LDLT from Febraury 1997 to December 2004 in a large-volume liver transplantation center was assessed retrospectively. Results: The model for end-stage liver disease score was 23±11, and mean pretransplant abstinence period was 16±13 months, with 14 (77.8%) patients being abstinent for at least 6 months. Graft types were right lobe grafts in 11, left lobe grafts in 2 and dual grafts in 5. Graft to recipient body weight ratio was 0.94±0.16. The relapse rates in patients who did and did not maintain 6 months of abstinence were 7.1% and 50%, respectively (p=0.097). Younger recipient age was a significant risk factor for alcohol relapse (p=0.027). Five recipients with antibody to hepatitis B surface antigen (HBsAg) received core antibody-positive liver graft, but two of them showed positive HBsAg seroconversion. Overall 5-year patient survival rate following LDLT was 87.8%, with a 5-year relapse rate of 16.7%. Conclusions: Pretransplant abstinence for 6 months appears to be benefical for preventing posttransplant relapse. Life-long prophylactic measure should be followed after use of anti-HBc-positive liver grafts regardless of hepatitis B viral marker status of the recipient. 
INTRODUCTION
Alcoholic liver disease (ALD) has been one of the most common causes of end-stage liver disease in Western countries, resulting in very high mortality rate in patients with advanced alcoholic cirrhosis and 7.9 deaths per 100,000 individuals in the United States. 1 As a result, alcoholic cirrhosis is one of the most common indications of liver transplantation in Western countries. We have presented the importance of pretransplant abstinence before. 2 In this study, we evaluated the long-term outcome of LDLT for ALD patients in a large-volume LDLT center.
METHODS
From February 1997 to December 2004, 789 adult-todult LDLTs were performed in our institution. Of these, 
RESULTS

Patient and donor demographics
The clinical profiles of the 18 patients are summarized in Table 1 . Fifteen patients (83.3%) manifested complications associated with portal hypertension. All patients underwent LDLT within 3 months of enrollment for LDLT.
Of the 18 patients, 4 (22.2%) did not meet the 6-month abstinence rule, but none of these underwent transplantation in urgent or emergency situations.
The demographic profiles of donors are summarized in Table 2 . All living donors were consanguineously or maritally related to the recipients. There was no ABO blood group-incompatible donor. All of these donors recovered uneventfully after liver donation operations.
Operation and surgical complications
Thirteen patients (72.2%) received single grafts, and 5
Fig. 1.
Cumulative overall and alcohol relapse-free survival curves of 18 alcoholic liver disease patients who underwent living donor liver transplantation. Overall 1-year, 3-year and 5-year patient survival rates were 100%, 100% and 87.8%, respectively (solid line). Relapse-free 1-year, 3-year and 5-year survival rates were 95.4%, 83.3% and 83.3%, respectively (dotted line). 
Survival outcome
Patients were followed-up for 36-111 months (mean, 57±20 months; median, 49 months). One patient, who had experienced clinical complications requiring intensive care after alcohol relapse, died from aspergillus pneumonia 36 months after transplantation. Another patient who also showed alcohol relapse died from suspected intractable relapse. The other 16 patients remain alive to date, resulting in overall 5-year survival rate of 87.8% (Fig. 1 ).
Two recipients who had concomitant hepatocellular carcinoma meeting the Milan criteria had no evidence of tumor recurrence over each 48 and 36 months. One patient was diagnosed of early gastric cancer 45 months after LDLT. He underwent resection and is doing well to date.
Alcohol relapse
Three recipients (16.7%) relapsed to alcohol abuse, after a mean of 9±8 months and a median of 15 months (Table 4) . One out of the 14 patients (7.1%) who had been abstinent for at least 6 months relapsed, but 2 out of the 4 patients (50%) who had been abstinent for less than 6 months relapsed (p=0.097). In contrast, younger age of recipients was a significant risk factor for alcohol relapse (41±8 years versus 53±6 years; p=0.027).
One-year and 3-year rates of alcohol relapse were 5.6% and 16.7%, respectively (Fig. 1) . Two patients drank moderate amounts of alcohol for a while, but their liver function became unstable on occasion. Changes in their liver function around the time of alcohol relapse are summarized in Table 5 .
After these periods of resumed drinking, one of these 3 patients did not become abstinent, leading to graft failure 44 months after LDLT. Another recipient start to drink at 2 months after LDLT, but he concealed it from us during monthly checkups. Five months after LDLT, this patient was admitted to hospital due to hepatorenal syndrome. After intensive care for 1 month, his liver function recovered progressively. However, he died from aspergillus pneumonia 36 months after LDLT (Fig. 2) .
Prevention of de novo hepatitis B
Nine recipients received one or two liver grafts positive for hepatitis B core antibody (anti-HBc). Patients who received liver grafts from anti-HBc-positive donors were ad- Alcohol relapse is a potential problem in liver transplantation to ALD patients, in which it can induce liver damage and deteriorate patient compliance to medications and clinic visits. 11 In practice, many liver transplant programs require 6 months of pretransplant abstinence prior to transplanation. However, many of these patients relapse to alcohol drinking, with some even returning to heavy alcohol consumption. However, there is little evidence
showing that resumption of drinking has a significant detrimental effect on graft or patient survival. 12 Posttransplant alcohol relapse in ALD patients does not have a significant effect on liver function or morphology, and the survival rate of these patients does not differ from that of patients who received DDLT for primary diseases other than ALD. 13 Furthermore, the long-term survival rates of relapsed and non-relapsed ADL patients were similar, suggesting that alcohol relapse did not decrease compliance with immunosuppressant medications. 14 It was shown that the liver function of patients who were abstinent after a period of alcohol relapse did not show additional deterioration. Fatty changes and pericellular fibrosis are the most relevant histological signs of heavy alcohol intake. 13 It was seen that alcoholic hepatic steatosis became reversed in this series. Although the 10-year survival rate of ALD recipients who relapsed has been reported to be significantly lower than that of individuals who remained abstinent, this decrease was not related to graft evolution, rejection, infection, or metabolic disturbance, but rather to a higher incidence of malignancies and cardiovascular events.
14 There are few reliable risk factors for alcohol relapse in ALD patients after liver transplantation. It has been suggested that the characteristics of pretransplant alcohol Abstinence for less than 6 months prior to liver transplantation may predict relapse and is widely employed as a criterion for listing for DDLT. 17 The result of this study did not show that abstinence for 6 months before LDLT was a statistically significant risk factor. However, the relaspe rate of 50% in the recipients who did not fulfill the 6-month abstistinence rule was definitely high comparing with 7.1% of recipients who met this rule. If the sample number had been a little larger than that in this study, there would be a statistically significant difference. We think that it is reasonable to emphasize the need to observe the 6-month abstistinence rule in ALD patients un-dergoing LDLT. [18] [19] [20] Early recognition of alcohol relapse during clinic visits is important for its effective management. Since relapse is considered shameful, relapsed patients are not willing to admit to it during clinic visits. In one patient with severe steatosis, we initially failed to suspect alcohol relapse after LDLT due to a preconceived notion regarding the recipient-donor relationship. Reliable objective tests for monitoring abstinence are required. Standard liver function tests are not helpful as they are non-specific, but definite deterioration of liver profiles may suggest that the patient has resumed drinking more than a moderate amount.
Assays of carbohydrate-deficient transferrin may be useful, because its concentration remains constant over weeks, comparable to that of hemoglobin A1c in diabetic patients. 21 This parameter, however, is not regarded as reli- ients. 22 Thus, a prophylactic regimen is mandatory to prevent de novo hepatitis in recipients. 2, 23, 24 In our institution, high-dose hepatitis B immunoglobulin has been used prophylactically in these patients.
In conclusion, it was shown that 6 months of abstinence prior to LDLT appear to be benefical for prevention of posttransplant alcohol relapse. Overall 5-year patient survival rate following LDLT was 87.8% in this series, with a 5-year relapse rate of 16.7%. Life-long prophylactic measure should be followed after use of anti-HBc-positive liver grafts regardless of hepatitis B viral marker status of the recipient.
